Biogen's Alzheimer's drug is struggling, and a turnaround might not be coming soon

Despite high expectations, the first drug ever approved in the U.S. to slow Alzheimer’s disease has not yet generated meaningful sales or been adopted by many of the country’s most prominent treatment centers.

The challenges facing Aduhelm, as the drug is called, were further detailed Wednesday, during its developer Biogen’s latest earnings call. Biogen has sought to get roughly 900 Alzheimer’s centers to use Aduhelm, but so far, only around 120 are doing so. And in its first full quarter on the market, Aduhelm sales totaled $300,000, well below the $16 million Wall Street analysts had forecasted.